- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06619509
En undersøgelse for at teste langtidsbehandling med Brigimadlin hos mennesker med solide tumorer, der deltog i en tidligere undersøgelse med denne medicin
Et fase II, enkelt-arm, åbent, langsigtet sikkerhedsforsøg med oral brigimadlin hos patienter med solide tumorer
This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was being developed to treat cancer.
All participants take brigimadlin as tablets once every 3 weeks at the study site. At study visits, doctors check participants' health and take note of any unwanted effects. At some study visits, doctors also check the size of the tumour and whether it has spread to other parts of the body. Participants are in the study as long as they benefit from treatment and can tolerate it.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
CABA, Argentina, C1120AAB
- Sanatorio Finochietto
-
-
-
-
New South Wales
-
Randwick, New South Wales, Australien, 2031
- Prince of Wales Hospital-Randwick-66496
-
-
Queensland
-
Woolloongabba, Queensland, Australien, 4102
- Princess Alexandra Hospital
-
-
-
-
-
Brussels, Belgien, 1200
- Cliniques Universitaires Saint-Luc
-
Leuven, Belgien, 3000
- UZ Leuven
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Arthur J. E. Child Comprehensive Cancer Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Cancer Centre
-
-
-
-
-
København Ø, Danmark, 2100
- Copenhagen University Hospital, Rigshospitalet
-
-
-
-
-
Cambridge, Det Forenede Kongerige, CB2 0QQ
- Addenbrooke's Hospital
-
London, Det Forenede Kongerige, SW3 6JJ
- The Royal Marsden Hospital, Chelsea
-
London, Det Forenede Kongerige, NW12PQ
- University College Hospital
-
-
-
-
California
-
Beverly Hills, California, Forenede Stater, 90212
- Precision NextGen Oncology
-
Santa Monica, California, Forenede Stater, 90403
- Sarcoma Oncology Center
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06511
- Yale Cancer Center
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32224
- Mayo Clinic Cancer Center
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63108
- Washington University School of Medicine
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68130
- Nebraska Cancer Specialists-Omaha-69066
-
-
New York
-
Lake Success, New York, Forenede Stater, 11042
- Northwell Health
-
-
Tennessee
-
Germantown, Tennessee, Forenede Stater, 38138
- West Cancer Center & Research Institute
-
Nashville, Tennessee, Forenede Stater, 37232
- Henry-Joyce Cancer Clinic
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- The University of Texas MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84106
- Utah Cancer Specialists Cancer Center
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98109
- Fred Hutchinson Cancer Research Center
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- University of Wisconsin
-
-
-
-
-
Lyon, Frankrig, 69373
- CTR Leon Berard
-
Rennes, Frankrig, 35042
- CTR Eugène Marquis
-
-
-
-
-
Tel Aviv, Israel, 6423906
- Sourasky Medical Center
-
-
-
-
-
Milan, Italien, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Padova, Italien, 35128
- Istituto Oncologico Veneto IRCCS
-
-
-
-
-
Fukuoka, Fukuoka, Japan, 812-8582
- Kyushu University Hospital
-
Fukuoka, Fukuoka, Japan, 811-1395
- National Hospital Organization Kyushu Cancer Center
-
Kanagawa, Yokohama, Japan, 241-8515
- Kanagawa Cancer Center
-
Miyagi, Sendai, Japan, 980-8574
- Tohoku University Hospital
-
Okayama, Okayama, Japan, 700-8558
- Okayama University Hospital
-
Osaka, Osaka, Japan, 541-8567
- Osaka International Cancer Institute
-
Tokyo, Chuo-ku, Japan, 104-0045
- National Cancer Center Hospital
-
-
-
-
-
Guangzhou, Kina, 510060
- Sun Yat-Sen University Cancer Center
-
-
-
-
-
Oslo, Norge, N-0379
- Oslo Universitetssykehus HF, Radiumhospitalet
-
-
-
-
-
Warsaw, Polen, 02-781
- Oncology Center-Maria Sklodowska-Curie Institute
-
-
-
-
-
Aragon, Spanien, 50009
- Hospital Universitario Miguel Servet
-
Madrid, Spanien, 28040
- Fundación Jiménez Díaz
-
Madrid, Spanien, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spanien, 28050
- Hospital Universitario HM Sanchinarro
-
Santiago de Compostela, Spanien, 15706
- Hospital Clínico de Santiago
-
-
-
-
-
Stockholm, Sverige, SE-171 76
- Karolinska Comprehensive Cancer Center
-
-
-
-
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
-
-
-
-
Olomouc, Tjekkiet, 77900
- University Hospital Olomouc
-
-
-
-
-
Berlin, Tyskland, 13125
- Helios Klinikum Berlin-Buch
-
Tübingen, Tyskland, 72076
- Universitätsklinikum Tübingen
-
-
-
-
-
Gyöngyös, Ungarn, 3200
- Clinexpert Gyongyos
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria:
- Patient is ongoing on brigimadlin treatment in any trial sponsored by Boehringer Ingelheim (hereafter referred to as the 'parent trial').
- Provision of signed and dated, written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses.
- Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use 2 medically acceptable methods of birth control per ICH M3 (R2) that result in a low failure rate of <1% per year when used consistently and correctly beginning at Screening, during trial participation, and until 6 months and 12 days after the last dose for women and 102 days after the last dose for men. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information.
- Participants must be willing and able to comply with the scheduled visits, treatment plan, lifestyle, laboratory tests, contraceptive guidelines, and other study procedures.
- Adequate organ function.
- Patient is eligible to receive continued treatment according to the clinical trial protocol of the parent trial they are currently participating in. Patients currently experiencing a dose delay in the parent trial due to adverse events are eligible if recovery from the adverse event takes place within the allowed time window in the parent trial.
Exclusion criteria:
- Any medical condition which in the opinion of the investigator should exclude the patient from receiving treatment with brigimadlin.
- Participants who must receive or intend to receive restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial. Female patients who do not agree to the interruption of breastfeeding from the start of study treatment until 6 months and 12 days after the last dose of study treatment.
- Patient has unacceptable toxicity on brigimadlin at the time of transition into this trial.
- Patient has an adverse event (AE) which has caused a dose delay and has not recovered within the allowed time window in the parent trial.
- Patient who has already required 2 dose reductions and would require a third dose reduction at trial entry, unless the investigator deems treatment continuation beneficial, and the third dose reduction is agreed in writing between the investigator and the sponsor.
Further exclusion criteria apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Brigimadlin
|
Brigimadlin
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The primary endpoint will be the occurrence of treatment-emergent adverse events (AEs) according to CTCAE Version 5.0 during the entire treatment period
Tidsramme: up to 9 years.
|
CTCAE=Common Terminology Criteria for Adverse Events |
up to 9 years.
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 1403-0032
- 2024-514177-21-00 (Registry Identifier: CTIS)
- U1111-1305-3484 (Registry Identifier: WHO International Clinical Trials Registry Platform (ICTRP))
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
IPD-delingstidsramme
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
IPD-delingsadgangskriterier
For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .